Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

38.25 -0.02 (-0.05%)

Delayed Quote Updated: 11:42 AM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Harmony Biosciences Holdings (NASDAQ:HRMY) Appears Undervalued with Strong Fundamentals ↗

November 15, 2025

Harmony Biosciences (HRMY) appears undervalued with a low P/E ratio, strong profitability, and impressive growth, suggesting a potential market opportunity.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Beats Q3 2025 Estimates Despite Muted Market Reaction ↗

November 04, 2025

Harmony Biosciences Q3 2025 earnings beat estimates with strong WAKIX growth. Despite the beat, stock dipped slightly in pre-market trading.

Via Chartmill

Topics Earnings

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

November 04, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Preview For Harmony Biosciences ↗

November 03, 2025

Via Benzinga

Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? ↗

October 23, 2025

Via Stocktwits

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime GARP Investment with Strong Growth and a Reasonable Price ↗

October 29, 2025

Harmony Biosciences (HRMY) offers strong growth at a reasonable price. With high EPS growth, robust profitability, and a low P/E ratio, it's a top GARP stock.

Via Chartmill

Q3 2025 Earnings Season: A Market Navigating AI's Ascent Amidst Economic Shifts

October 23, 2025

The curtain has largely fallen on the Q3 2025 earnings season, revealing a financial landscape characterized by robust corporate performance, particularly in the technology and financial sectors,...

Via MarketMinute

Topics Artificial Intelligence Economy Fraud

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

October 23, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Undervalued Investment Case ↗

October 20, 2025

Harmony Biosciences (HRMY) is a value stock with a low P/E ratio, strong profitability, a healthy balance sheet, and solid growth potential.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY): A Growth Stock with a Promising Technical Setup ↗

October 16, 2025

Harmony Biosciences (HRMY) offers strong growth, high profitability, and an attractive valuation. Its positive technical setup suggests a potential breakout, making it a compelling stock to watch.

Via Chartmill

Top 3 Health Care Stocks That Are Preparing To Pump In Q4 ↗

October 06, 2025

Via Benzinga

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents an 'Affordable Growth' Opportunity ↗

September 26, 2025

Harmony Biosciences (HRMY) offers affordable growth with strong EPS & revenue expansion, a low P/E ratio, and robust profitability in rare neurological treatments.

Via Chartmill

Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (6 Ratings) ↗

September 25, 2025

Analysts' ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below...

Via Benzinga

Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday ↗

September 24, 2025

Via Benzinga

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study ↗

September 24, 2025

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

Via Stocktwits

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study ↗

September 24, 2025

Harmony Biosciences' ZYN002 failed to meet its primary goal in a Fragile X Phase 3 trial, but the company points to pipeline growth.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 24, 2025

Via Benzinga

Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble ↗

September 24, 2025

Shares plunged Wednesday as the inherited disease continued to be "undruggable" for the biotech company.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 24, 2025

Via Benzinga

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

September 24, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity ↗

September 18, 2025

Harmony Biosciences (HRMY) is a value stock with strong fundamentals: low P/E, high profitability, robust financial health, and impressive growth prospects.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Top Affordable Growth Stock ↗

September 04, 2025

Harmony Biosciences (HRMY) exemplifies GARP investing with strong EPS growth, a low P/E ratio, and robust profitability in the rare neurology sector.

Via Chartmill

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

August 26, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity ↗

August 22, 2025

Harmony Biosciences (HRMY) is a value stock with strong fundamentals: undervalued P/E, high profitability, robust financial health, and impressive growth metrics.

Via Chartmill

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

August 21, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime Affordable Growth Stock with Strong Fundamentals ↗

August 13, 2025

Harmony Biosciences (HRMY) offers strong growth, solid valuation, and financial health, making it an ideal pick for Affordable Growth investors seeking high potential at reasonable prices.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY): A Strong Growth Stock with Promising Technical Setup ↗

August 09, 2025

Harmony Biosciences (HRMY) offers strong growth potential with solid fundamentals, high profitability, and a bullish technical setup, making it an attractive stock for investors.

Via Chartmill

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

August 05, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.